The rising cancer crisis in year two of COVID-19

The fear of exposure to Covid-19 coupled with the temporary shutdown of non-emergency health services put millions of people off routine healthcare screenings. Now, in the second year of the pandemic, a wave of cancer diagnoses is revealing a new crisis.

That’s the scene painted by ProPublica in a recent report about some of the cancer patients receiving late-stage diagnoses as a result of delays in routine care during the pandemic. It’s been well documented that cancer screenings and other care services dropped off steeply during the beginning months of the pandemic. Many physician offices closed or stopped seeing patients in person altogether for a period of time. Adults delayed care, while many parents put off care for their children, as well.

Preventive cancer screenings dropped 94% in the first four months of 2020, according to ProPublica.

“Amid the damage is an untold number of cancers that went undiagnosed or untreated as patients postponed annual screenings, and as cancer clinics and hospitals suspended biopsies and chemotherapy and radiation treatments,” ProPublica reported. 

And the damage is expected to come in an excess of 100,000 cancer deaths over the next decade, according to the National Cancer Institute.

See the full story below:

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.